Christopher Richard Anzalone, Chief Executive Officer at ARROWHEAD PHARMACEUTICALS, INC. (ARWR), sold 110,000 shares at $67.97 ($7.6M) on 2020-12-08, disclosed to the SEC on 2020-12-10.
Open-market sale of $7.6M ARWR by Chief Executive Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $67.97 | 16,324 | $1.1M | 14.7% |
| 2 | $67.97 | 16,324 | $1.1M | 14.7% |
| 3 | $67.27 | 16,726 | $1.1M | 14.9% |
| 4 | $67.27 | 16,726 | $1.1M | 14.9% |
| 5 | $69.80 | 12,067 | $842K | 11.1% |
| 6 | $69.80 | 12,067 |
| $842K |
| 11.1% |
| 7 | $70.87 | 5,880 | $417K | 5.5% |
| 8 | $70.87 | 5,880 | $417K | 5.5% |
| 9 | $71.61 | 4,003 | $287K | 3.8% |
| 10 | $71.61 | 4,003 | $287K | 3.8% |
| Total | $68.73 avg | 110,000 | $7.6M | 100% |
| Filing → |
| ARWR | SELL | 2025-12-23 | $3.5M | — | Filing → |
| ARWR | SELL | 2025-12-19 | $10.9M | — | Filing → |
| ARWR | SELL | 2025-12-16 | $24.6M | — | Filing → |